Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians - PubMed (original) (raw)

. 1997 Nov;71(11):8908-11.

doi: 10.1128/JVI.71.11.8908-8911.1997.

J Krowka, C Santamaria, K Balsamo, F Gao, G Mulundu, C Luo, N N'Gandu, H Sheppard, B H Hahn, S Allen, J A Frelinger

Affiliations

• PMID: 9343257
• PMCID: PMC192363
• DOI: 10.1128/JVI.71.11.8908-8911.1997

Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians

M R Betts et al. J Virol. 1997 Nov.

Abstract

We have examined cross-clade HIV-specific cytotoxic T-lymphocyte (CTL) activity in peripheral blood of eight Zambian individuals infected with non-B-clade human immunodeficiency virus type 1 (HIV-1). Heteroduplex mobility assay and partial sequence analysis of env and gag genes strongly suggests that all the HIV-infected subjects were infected with clade C HIV-1. Six of eight C-clade HIV-infected individuals elicited CTL activity specific for recombinant vaccinia virus-infected autologous targets expressing HIV gag-pol-env derived from B-clade HIV-1 (IIIB). Recognition of individual recombinant HIV-1 B-clade vaccinia virus-infected targets expressing gag, pol, or env was variable among the patients tested, indicating that cross-clade CTL activity is not limited to a single HIV protein. These data demonstrate that HIV clade C-infected individuals can mount vigorous HIV clade B-reactive CTL responses.

PubMed Disclaimer

Similar articles

• Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
  Wilson SE, Pedersen SL, Kunich JC, Wilkins VL, Mann DL, Mazzara GP, Tartaglia J, Celum CL, Sheppard HW. Wilson SE, et al. AIDS Res Hum Retroviruses. 1998 Jul 20;14(11):925-37. doi: 10.1089/aid.1998.14.925. AIDS Res Hum Retroviruses. 1998. PMID: 9686639
• Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.
  Durali D, Morvan J, Letourneur F, Schmitt D, Guegan N, Dalod M, Saragosti S, Sicard D, Levy JP, Gomard E. Durali D, et al. J Virol. 1998 May;72(5):3547-53. doi: 10.1128/JVI.72.5.3547-3553.1998. J Virol. 1998. PMID: 9557634 Free PMC article.
• Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.
  Cao H, Kanki P, Sankalé JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, Walker BD. Cao H, et al. J Virol. 1997 Nov;71(11):8615-23. doi: 10.1128/JVI.71.11.8615-8623.1997. J Virol. 1997. PMID: 9343219 Free PMC article.
• Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines.
  Ferrari G, Kostyu DD, Cox J, Dawson DV, Flores J, Weinhold KJ, Osmanov S. Ferrari G, et al. AIDS Res Hum Retroviruses. 2000 Sep 20;16(14):1433-43. doi: 10.1089/08892220050140982. AIDS Res Hum Retroviruses. 2000. PMID: 11018863 Review.
• Virus-specific cytotoxic T lymphocyte responses in patients infected with the human immunodeficiency virus, HIV-1.
  Rivière Y. Rivière Y. Cell Mol Biol (Noisy-le-grand). 1994;40 Suppl 1:45-8. Cell Mol Biol (Noisy-le-grand). 1994. PMID: 7950861 Review.

Cited by

• Early Presence of HIV-1 Subtype C in Washington, D.C.
  Grossman Z, Rico SV, Cone K, Shao W, Rehm C, Jones S, Bozzi G, Dean S, Dewar R, Rehman T, Purdy J, Hadigan C, Pau AK, Maldarelli F. Grossman Z, et al. AIDS Res Hum Retroviruses. 2018 Aug;34(8):680-684. doi: 10.1089/AID.2018.0041. AIDS Res Hum Retroviruses. 2018. PMID: 29936863 Free PMC article.
• Human immunodeficiency virus vaccines.
  Goepfert P, Bansal A. Goepfert P, et al. Infect Dis Clin North Am. 2014 Dec;28(4):615-31. doi: 10.1016/j.idc.2014.08.004. Epub 2014 Oct 5. Infect Dis Clin North Am. 2014. PMID: 25287587 Free PMC article. Review.
• T-cell immune responses against Env from CRF12_BF and subtype B HIV-1 show high clade-specificity that can be overridden by multiclade immunizations.
  Mónaco DC, Rodríguez AM, Pascutti MF, Carobene M, Falivene J, Gómez A, Maeto C, Turk G, Nájera JL, Esteban M, Gherardi MM. Mónaco DC, et al. PLoS One. 2011 Feb 18;6(2):e17185. doi: 10.1371/journal.pone.0017185. PLoS One. 2011. PMID: 21364754 Free PMC article.
• Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.
  Promkhatkaew D, Pinyosukhee N, Thongdeejaroen W, Teeka J, Wutthinantiwong P, Leangaramgul P, Sawanpanyalert P, Warachit P. Promkhatkaew D, et al. Immunol Invest. 2009;38(8):762-79. doi: 10.3109/08820130903070544. Immunol Invest. 2009. PMID: 19860587 Free PMC article.
• Design and pre-clinical evaluation of a universal HIV-1 vaccine.
  Létourneau S, Im EJ, Mashishi T, Brereton C, Bridgeman A, Yang H, Dorrell L, Dong T, Korber B, McMichael AJ, Hanke T. Létourneau S, et al. PLoS One. 2007 Oct 3;2(10):e984. doi: 10.1371/journal.pone.0000984. PLoS One. 2007. PMID: 17912361 Free PMC article.

References

1. 1. AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1329-39 - PubMed
2. 1. J Virol. 1996 Feb;70(2):1100-8 - PubMed
3. 1. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Jan 1;14(1):1-6 - PubMed
4. 1. J Virol. 1997 Feb;71(2):1256-64 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1396-401 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • MedlinePlus Health Information